HIV Patients

View All

pharma-news
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result

Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases The engineered exosome technology is believed to improve the delivery of delivering gene therapy, gene editing and RNA technologies for ne...

Find More